Background
==========

Hemophilia represents the most common and severe inherited hemorrhagic disorder. Hemophilia A(HA) is caused by mutations in the F8 gene, leading to a deficiency or dysfunctional III protein, an essential cofactor in the factor X activation complex. The F8 gene is 186 kb long; it has 26 exons and encodes a 9-kb mRNA transcript \[[@B1],[@B2]\]. The mutations causing hemophilia A are spread throughout the gene and are mostly represented by point alterations. However, the inversion of intron 22 was found in 40--50% of patients with severe HA \[[@B3]\] and the inversion of intron 1 was reported with a prevalence of about 5% in the UK \[[@B4]\].

Patients suffering from the disorder, along with their families, bear great financial and social burden; therefore, it is very important to prevent recurrence of the disease. For the sake of genetic counselling and prenatal diagnosis of hemophilia A, it is necessary to establish a sensitive, rapid and economic genetic diagnostic system. However, comprehensive analysis of mutations in the F8 gene is difficult to conduct due to the large gene size, its many scattered exons, and the high frequency of de novo mutation. The most direct strategy for mutation detection would be to amplify these regions from genomic DNA using PCR \[[@B5]\]. However, it would necessitate almost 30 amplifications of genomic DNA to cover all the essential regions.

The first systematic analysis of the complete coding sequence of the F8 gene was performed by applying denaturing gradient gel electrophoresis (DGGE) after PCR amplification in 1991. The analysis demonstrated a 90% mutation detection rate \[[@B6]\]. Since then, a wide range of different mutations have been identified, providing the genetic basis for the extensive variability observed in the clinical phenotypes. Mutation detection in the F8 gene is so challenging that it is only partially met by conventional screening methods such as single stranded conformational polymorphism (SSCP), conformational sensitive gel electrophoresis (CSGE) and chemical mismatch cleavage (CMC), each with varying applicability and efficiency; however, they all suffer from incomplete detection rates in the range of 70--85% \[[@B7]-[@B11]\]. Moreover, each method places variable demands on the technical skills and time investment of the investigator. In contrast, the recently introduced denaturing high performance liquid chromatography (DHPLC) offers a promising new method for a fast and sensitive analysis(96.2%) of PCR-amplified DNA segment \[[@B12]-[@B15]\].

We have established a diagnostic strategy, consisting of screening for most common mutations in the F8 gene, using long-distance polymerase chain reaction (LD-PCR) and DHPLC. We reported the result of detailed screening of 122 Taiwan families with hemophilia A. In order to facilitate throughput and minimize the cost of mutation scanning, we also evaluated a new mutation scanning technique, high resolution melting analysis (HRM). This alternative screening technique detects sequence variation by the use of a saturating double-stranded DNA dye.

Methods
=======

Patients
--------

This study was approved by the Ethic Institute Review Board of National Taiwan University Hospital and included 122 families, in which 329 samples had hemophilia A family history. We obtained consent from each subject. The patients presented varying degrees of severity of the disease. The mild and moderate hemophilia A was diagnosed following the familial transmission analysis and after the elimination of von Willebrand disease type 2N either by FVIII:vWF binding test or sequencing of exon 18 to 24 of the von Willebrand gene.

DNA extraction
--------------

According to the manufacturer\'s instructions, genomic DNA was extracted from 3 ml of peripheral blood cell samples with a Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN).

DNA mutation numbering is based on cDNA sequence and nucleotide +1 corresponds to A of the ATG translation initiation codon. The nomenclature of this study follows the Nomenclature for Description of Genetic Variations approved by the Human Genome Variation Society and differs in 19 amino acids from the reference mutation database because the first 19 amino acids compose a signal peptide.

Mutation identification
-----------------------

### The PCR assay for intron 22 inversion

The PCR mixture contained a total volume of 50 μl: 1 mM 10× buffer, 76 mM DMSO, 0.5 mM of dNTP and 0.3 mM deaza-Dgtp(Amershan Biosciences; Freiburg Germany), 0.12 mM of Expand long Template DNA polymerase (Roches) and 0.36 mM each of primer P, Q, 0.06 mM each of primer A, B as described by Qiang Liu et al. \[[@B16],[@B17]\]. Subcycling multiplex long distance PCR(LD-PCR) was carried out as described by Qiang Liu et al. \[[@B16],[@B17]\] with slight modifications in the reaction temperatures. The conditions for LD-PCR for the first 10 cycles were set at 94°C for 12s, followed by four subcycles of annealing/elongation carried out at 62°C for 120s and 65°C for 120s. The remaining 20 cycles were modified by the addition of an extra 5s per cycle for each of the annealing/elongation step. 10 μl of PCR product were mixed with TAE buffer and electrophoresed for one hour on a 0.7% agarose gel, then stained with ethidium bromide and visualized under UV Light.

### The PCR assay for intron 1 inversion

The PCR amplification of the F8 intron 1 region and the intron 1 h repeats were performed on 100 ng of genomic DNA, in a reaction volume of 25 μl containing 0.1 mM dNTP, 2 mM MgCl~2~, 10 mM buffer and 0.5 units Taq polymerase (Perkin Elmer, ABI Foster City, CA). The primers used for the amplification of the F8 intron 1 region were 0.12 mm of 9F, 9CR and int1h-2F each. Primers int1h-2F, int1h-2R and 9F were used for the amplification of intron 1 h repeats as previously described by Tizzano and Banagnall et al. \[[@B18],[@B19]\]. After the initial denaturing step at 95°C for 5 min, thirty cycles of PCR were carried out designated at 94°C for 30s, 65°C for 30s and 72°C for 2 min. Finally, 5 μl of PCR products were mixed with TAE buffer and electrophoresed for one hour on a 0.7% agarose gel, then stained with ethidium bromide and visualized under UV light.

### PCR assay and DHPLC for entire coding region

If there was no inversion in intron 1 or intron 22, we perform mutation analysis of the entire F8 coding region, including flanking splicing sites, by DHPLC using appropriate primers (Table [1](#T1){ref-type="table"}). The DHPLC allows for the automated detection of single base DNA substitutions as well as small insertions and deletions. When using heteroduplex analysis by DHPLC under partially-denaturing conditions, heteroduplexes are retained less than their corresponding homoduplexes on a unique DNA separation matrix. DHPLC uses unpurified PCR products that are subjected to a final denaturing/reannealing step to ensure adequate formation of the heteroduplex. The cycling parameters of the amplification reactions were optimized for the fragment. Equal volumes of the polymerase chain reaction (PCR) product from the patient and from a wild-type control male were mixed, denatured at 95°C for 5 min and then incubated at 65°C for 30 min to obtain heteroduplexes. Mutational screening, performed on all amplified fragments from each patient, was carried out via denaturing high-performance liquid chromatography (DHPLC) on a Wave^®^DNA Fragment Analysis System (Transgenomic Inc., San Jose, CA) with a DNASep column (Transgenomic). The DNASep column contains proprietary 2-mm nonporous alkylated poly (styrene divinylbenzene) particles. The DNA molecules eluted from the column are detected by scanning with a UV detector at 260 nm. DHPLC-grade acetonitrile (9017-03; J.T. Baker, Phillipsburg, NJ) and triethylammonium acetate (TEAA; Transgenomic, Crewe, UK) constituted the mobile phase \[[@B14],[@B20]\]. For DHPLC analysis, heterozygous profiles were identified by visual inspection of the chromatograms.

###### 

Primer pairs and PCR conditions for DHPLC analysis.

  HA Primer pairs and PCR conditions for DHPLC analysis                                                                                                                                        
  ------------------------------------------------------- ------------------------------ ----------------------------- ---------------------- ----------------- --------------------- -------- --------
  Exon primer                                             Sequence (5\' to 3\')          Length of PCR amplicon (bp)   Annealing Temp. (°C)   DHPLC oven (°C)   Elution profile(B%)            
                                                                                                                                                                                               
  1F                                                      ACATCCAGTGGGTAAAGTTC           356                           53                     60                55                    56--65   52--61
  1R                                                      AGACTTACATCCCCACAATC                                                                                                                 
  2F                                                      TTGAAGTGTCCACCAAAATGAACGACT    211                           54                     59                                      48--57   
  2R                                                      GATACCCAATTTCATAAATAGCATTCA                                                                                                          
  3F                                                      GTACTATCCCCAAGTAACCTT          204                           54                     59                                      50--59   
  3R                                                      CATAGAATGACAGGACAATAGG                                                                                                               
  4F                                                      TACAGTGGATATAGAAAGGAC          296                           54                     57                                      54--63   
  4R                                                      TGCTTATTTCATCTCAATCCTACGCTT                                                                                                          
  5F                                                      CCTCCTAGTGACAATTTCCTA          188                           54                     55                                      49--58   
  5R                                                      AGCAGAGGATTTCTTTCAGGAATCCAA                                                                                                          
  6F                                                      CATGAGACACCATGCTTAGCT          224                           54                     60                                      51--60   
  6R                                                      AACTCTGGTGCTGAATTTGGAAGACCCT                                                                                                         
  7F                                                      CAGATTCTCTACTTCATAGCCATAG      324                           54                     58                56                    55--64   53--62
  7R                                                      ATTAAAAGTAGGACTGGATA                                                                                                                 
  8F                                                      ATATAGCAAGACACTCTGACA          338                           54                     58                                      55--64   
  8R                                                      AGAGAGTACCAATAGTCAAA                                                                                                                 
  9F                                                      AGAGTTGGATTTGAGCCTACC          284                           54                     58                55                    53--62   50--59
  9R                                                      CAGACTTTTTCTTCTTACCTGACCTT                                                                                                           
  10F                                                     GGATTTGATCTTAGATCTCGC          204                           53                     56                54                    50--59   48--57
  10R                                                     ATTTTAGTTGTTATTGATGA                                                                                                                 
  11F                                                     TTGAGCTATTTATGGTTTTG           294                           53                     58.5              56                    53--62   51--60
  11R                                                     GACATACACTGAGAATGAA                                                                                                                  
  12F                                                     GCATTTCTTTACCCCTTTCA           230                           54                     59.5              57                    51--60   49--58
  12R                                                     CTTTATTCACCACCCACTG                                                                                                                  
  13F                                                     TCCTGGGAATAAGATAATGG           393                           54                     57.5              56                    56--65   54--63
  13R                                                     AGAGCATACGAATGGCTAGT                                                                                                                 
  14(I)F                                                  ATCTGTGTTATGAGTAACCA           430                           54                     57.5                                    57--66   
  14(I)R                                                  TCATATTTGGCTTCTTGGAG                                                                                                                 
  14(II)F                                                 CATGGGCTATCCTTATCTGA           479                           54                     56.5                                    57--66   
  14(II)R                                                 CATGAACTTTCTTGGCTATT                                                                                                                 
  14(III)F                                                TCAAAGTTGTTAGAATCAGG           441                           54                     55.5                                    56--65   
  14(III)R                                                ATTTTGTGCATCTGGTGGAA                                                                                                                 
  14(IV)F                                                 GTCCAACAGAAAAAAGAGGG           481                           54                     57                54.5                  58--67   55--64
  14(IV)R                                                 CTACATTTTGCCTAGTGCTC                                                                                                                 
  14(V)F                                                  CTGGCACTAAGAATTTCATG           429                           54                     57.5              56                    57--66   55--64
  14(V)R                                                  CCTTCTCATTGTAGTCTATC                                                                                                                 
  14(VI)F                                                 GAAACATTTGACCCCGAGCA           431                           54                     57.5                                    56--65   
  14(VI)R                                                 TTTTGGGCAAGTCTGGTTTC                                                                                                                 
  14(VII)F                                                CACATACAAGAAAGTTGAGA           436                           54                     59                57.5                  56--65   55--64
  14(VII)R                                                CTCATTTATTGCTGCTATTG                                                                                                                 
  14(VIII)F                                               GATACCATTTTGTCCCTGAA           415                           54                     57.5                                    56--65   
  14(VIII)R                                               GTCACAAGAGCAGAGCAAAG                                                                                                                 
  15F                                                     CACCTAGGAAAATGAGGATGT          300                           53                     58.5              56                    53--62   51--60
  15R                                                     ATAGTCAGCAAGAAAATAAA                                                                                                                 
  16F                                                     AAGATCCTAGAAGATTATTC           330                           50                     57.5                                    53--62   
  16R                                                     TTAGTACACAAAGACCATTT                                                                                                                 
  17F                                                     TGATGAGAAATCCACTCTGG           349                           54                     58                56.5                  54--63   53--62
  17R                                                     GTGCAATCTGCATTTCACAG                                                                                                                 
  18F                                                     GTGGAATCCTCATAGATGTCA          312                           53                     57                                      54--63   
  18R                                                     GAGTAGGTAGAAGAAAGAGCAC                                                                                                               
  19F                                                     GCAAGCACTTTGCATTTGAG           305                           52                     59                56                    55--64   52--61
  19R                                                     AGCAACCATTCCAGAAAGGA                                                                                                                 
  20F                                                     CCATTTTCATTGACTTACATTTGAG      193                           53                     59.5              56.5                  49--58   46--55
  20R                                                     AGATATAATCAGCCCAGGTTC                                                                                                                
  21F                                                     GAATTTAATCTCTGATTTCTCTAC       168                           53                     60.5              56                    48--57   46--55
  21R                                                     GAGTGAATGTGAATACATTTCC                                                                                                               
  22F                                                     AAATAGGTTAAAATAAAGTGTTAT       206                           53                     48                                      48--57   
  22R                                                     GACTAATTACATACCATTAAG                                                                                                                
  23F                                                     CTCTGTATTCACTTTCCATG           250                           54                     57                                      52--61   
  23R                                                     ACAGTTAGTCACCCTACCCA                                                                                                                 
  24F                                                     GCTCAGTATAACTGAGGCTG           249                           54                     58.5                                    51--60   
  24R                                                     CTCTGAGTCAGTTAAACAGT                                                                                                                 
  25F                                                     AGTGCTGTGGTATGGTTAAG           323                           56                     58                56.5                  55--64   54--63
  25R                                                     TTGCTCTGAAAATTTGGTCATA                                                                                                               
  26F                                                     ATCCTGGACTACTGGAAACA           393                           53                     63                58.5                  56--65   51--60
  26R                                                     AGTTAATTCAGGAGGCTTCA                                                                                                                 

Samples showing an abnormal peak pattern were sequenced using a fluorescent ABI Prism BigDye terminator kit (Applied Biosystems, UK), and the mutations were characterized. Each mutation was confirmed on a second, independent, amplified PCR sample. In order to rule out the possibility of exonic polymorphisms, 150 DNA samples from healthy, unrelated controls were screened and found negative for the novel missense mutations. All mutations found in the patients\' family members were confirmed by sequencing.

High Resolution Melting Analysis
--------------------------------

Melting curve analysis with the high-resolution melting instrument is a simple, high-performance, reliable, high-resolution, time-saving, and low labor-intensive technique that has shown promise as a sensitive and specific tool for the detection of variations in DNA. The thermal stability of a PCR product is determined by its base sequence \[[@B21],[@B22]\]. When the PCR product sequence is altered, duplex stability is changed, leading to different melting behavior. During high resolution melting analysis, melting curves are produced using dyes that fluoresce in the presence of double-stranded DNA and specialized instruments designed to monitor fluorescence during heating; as the temperature increases, the fluorescence decreases, producing a characteristic melting profile. The melting curve data were normalized, temperature-shifted, and converted to melting peaks by plotting the negative derivative of the fluorescence with respect to temperature against temperature (-dF/dT vs. temperature). This melting data can be analyzed to detect sequence variations such as single nucleotide polymorphisms and small insertions and deletions.

PCR amplification mixture included 2.5 mM MgCl~2~, 5 μl 2× Master Mix, 3.1 μl H2O (from Roche Reaction Mix Kit, Mannheim, Germany), 0.2 mM primers. And we added 25 ng DNA template. PCR amplification began with the first denaturation step at 95°C for 10 min, followed by 25 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 45 s, extension at 72°C for 45 s, and then a final extension step at 72°C for 10 min.

Pipet 10 μl PCR products into each well of the LightCycler^®^480 (Roche Applied Science) Multiwell Plate. Seal Multiwell Plate with LightCycler^®^480 Sealing Foil. Load the multiwall Plate in LightCycler^®^480 instrument and start the melting program. High resolution melting was performed at 95°C for 1 min, 40°C for 1 min, 6.5°C for 1 s and acquisitions at 95°C. The data was evaluated using the LightCycler^®^480 Gene Scanning Software.

In order to improve the melting analysis, we redesigned the primers for some exons to shorten the PCR product and to avoid DNA-dimer formation (Table [2](#T2){ref-type="table"}).

###### 

Redesigned primer pairs for HRM

  Exon           Oligo (5\' -- 3\')           product size
  -------------- ---------------------------- --------------
  HA -- 1-1F     CCACTGATAAAAAGGAAGCA         226
  HA -- 1-1R     GTGGAGAGCTCTATTTGCAT         
  HA -- 1-2F     CCTCCTGGGAGCTAAAGATA         248
  HA -- 1-2R     CGATCAGACCCTACAGGA           
  HA -- 4-1F     CTTTGAGTGTACAGTGGATATAGAA    200
  HA -- 4-1R     AAAGATATGAGTAGGTAAGGCACA     
  HA -- 4-2F     TGATAAAGTCTTCCCTGGTG         209
  HA -- 4-2R     TGCTTATTTCATCTCAATCCT        
  HA -- 7-1F     CCTAGCAAGTGTTTTCCATT         246
  HA -- 7-1R     AGGTCCATCAAGAGTGTTTG         
  HA -- 7-2F     GCCACAGGAAATCAGTCTAT         236
  HA -- 7-2R     TTCATTTTAAAGATCCAAGA         
  HA -- 8-1F     TGAGCCAATTCAATCTCTTT         237
  HA -- 8-1R     ATCATCAAACCTGACCACAT         
  HA -- 8-2F     TAATGAAGAAGCGGAAGACT         245
  HA -- 8-2R     TTTTGAGTATGGGGAAGAGA         
  HA -- 9F       CCCAACCTCTCATCTTTTT          250
  HA -- 9R       CCAGACTTTTTCTTCTTACCTG       
  HA -- 11-1F    CAGATTTGTAGAACCCTTGC         216
  HA -- 11-1R    TAGAGTAATAGCGGGTCAGG         
  HA -- 11-2F    CTGCCAGGAGAAATATTCAA         239
  HA -- 11-2R    AAGGGGACATACACTGAGAA         
  HA -- 13-1F    CATGACAATCACAATCCAAA         244
  HA -- 13-1R    AGAATGGGAATAGGGTGAGT         
  HA -- 13-2F    GAGGTGGCATACTGGTACAT         219
  HA -- 13-2R    ATACGAATGGCTAGTGAAGC         
  HA -- 14-1F    CTGTGTTATGAGTAACCAGAGT       243
  HA -- 14-1R    CCTAGTGCTAGGGTGTCTTG         
  HA -- 14-2F    AATGCCATTGAACCAAGA           238
  HA -- 14-2R    CATATTTGGCTTCTTGGAGA         
  HA -- 14-3F    TCTTGCGACAGAGTCCTACT         242
  HA -- 14-3R    TTTCTTCAACTCTGTTGCTG         
  HA -- 14-4F    TCAGGCCTCCAATTAAGAT          250
  HA -- 14-4R    GGTCCACCAGACTCAGTAAG         
  HA -- 14-5F    AGA TAC CAC TCT ATT TGG CA   229
  HA -- 14-5R    AAC TTT GAA TAA GGC ATT A    
  HA -- 14-6F    TGGTAGGTTATTTAAAGGGAAA       248
  HA -- 14-6R    GCATTCTGTCATGAATCAAA         
  HA -- 14-7F    CCATCAGTCTGGCAAAATA          250
  HA -- 14-7R    ATCCACCTTGCTGATTCTG          
  HA -- 14-8F    CACAAAATCCAGATATGTCGT        235
  HA -- 14-8R    CCATCTCTTTGAGTCCTACG         
  HA -- 14-9F    AGGAAAGGGTGAATTTACAA         249
  HA -- 14-9R    TTTTGCCTAGTGCTCAGTAA         
  HA -- 14-10F   TTGCCTCAGATACATACAGTG        250
  HA -- 14-10R   TGCATGCATATTTCTCTACAA        
  HA -- 14-11F   AAAACTTGGAAGGCTTGG           250
  HA -- 14-11R   TTGTAGTCTATCTGTGTGAGG        
  HA -- 14-12F   GGTCCAAAAACATGAAACAT         245
  HA -- 14-12R   ATAAGATGCTGCTGGAAGAT         
  HA -- 14-13F   GGTCCTATTCCAAGACAACTC        250
  HA -- 14-13R   AGATGTTTTGGGCAAGTCT          
  HA -- 14-14F   CACATACAAGAAAGTTGAGAACA      250
  HA -- 14-14R   GCTTTCTGTTGCTACTCTCAG        
  HA -- 14-15F   TGGAATGAAGCAAACAGAC          250
  HA -- 14-15R   TTTGTCCCTCATTTATTGCT         
  HA -- 14-16F   ATACCATTTTGTCCCTGAAC         249
  HA -- 14-16R   TGTCAAAATCTTCCTTCTTCA        
  HA -- 14-17F   TTCAGTCAGATCAAGAGGAAA        246
  HA -- 14-17R   TCAAATGTCACAAGAGCAGA         
  HA -- 15F      TATTGCTTTTCCTCTGCTTT         214
  HA -- 15R      TTTCTTGTAATTCCACTGTCC        
  HA -- 16-1F    GGGATGTAAACCCTAAGGAC         228
  HA -- 16-1R    ATGATGTTGCACTTTCCAA          
  HA -- 16-2F    CTCTCGTCCCTATTCCTTCT         232
  HA -- 16-2R    TAAACCAAAAAGTGGTCAGC         
  HA -- 17-1F    ACTCATAGGATTGATGTCTTCC       238
  HA -- 17-1R    TAAAAGTGGGATCTTCCATC         
  HA -- 17-2F    CTAACACACTGAACCCTGCT         241
  HA -- 17-2R    TCATTTGTCAAAGTGCAATC         
  HA -- 18F      TTTTAACAGGCTTCTCTGTG         246
  HA -- 18R      AGGTAGAAGAAAGAGCACAAAC       
  HA -- 19F      AAATAATTTCTGTTCCTGTTG        222
  HA -- 19R      ATTCCAGAAAGGAAGAAAGC         
  HA -- 25-1F    GGT GAC CAA GAG GCT AC       170
  HA -- 25-1R    GAC TGC TGG AGA TGA GGA      
  HA -- 25-2F    CAG GGA GTA AAA TCT CTG C    155
  HA -- 25-2R    TGG TAT TTT TTT TCT TTC TT   
  HA -- 26-1F    AGAAGTGAGAAAAGCGTCTG         244
  HA -- 26-1R    ACCCTCAGTAGAGGTCCTG          
  HA -- 26-2F    GAATTCACCCCCAGAGTT           234
  HA -- 26-2R    AGAAATGCAGGACTGATGAT         

Some of the primers used for HRM were redesigned by LightCycler Probe Design Software 2.0. The primers not listed were the same with table 1

Multiplex PCR by Capillary Electrophoresis
------------------------------------------

In one family, the band of exon 4 to exon 10 by electrophoresis after PCR was visible in female cases but not in affected male patients. Large deletion was suspected, so we designed multiplex PCR in order to differentiate normal female from female carriers.

Multiplex PCRs were used to optimize the system and allowed the amplification of exon 3 to exon11. The KRIT and FGFR2 genes were used as internal controls. Each multiplex PCR for the DNA fragments was performed in a total volume of 25 μL containing the following: 100 ng of genomic DNA; 0.1 to 0.5 μM each primer; 200 μM dNTPs; 1 unit of AmpliTaq Gold enzyme (PE Applied Biosystems); and 2.5 μL of GeneAmp 10× buffer II (10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl) in 2 mM MgCl~2~as provided by the manufacturer. PCR amplification was carried out with an initial denaturation step at 95°C for 10 min, followed by 25 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 45 s, extension at 72°C for 45 s, and then a final extension step at 72°C for 10 min.

The HDA system with GCK-5000 cartridge kit (eGene) was used to analyze exons of the F8 gene. The gel-matrix in the gel cartridge consists of proprietary linear polymer with ethidiumbromide (EtBr) dye. The PCR products were diluted 20-fold by deionized water and placed in the sample chamber of the instrument. The DNA samples were then automatically injected into the capillary channel and subjected to electrophoresis according to the manufacturer\'s operation protocol. BioCalculator Graphing software (eGene) enabled automatic labelling of the peak sizes.

Results
=======

Genomic DNA from 122 HA unrelated families were analyzed for mutations in the F8 gene (Table [3](#T3){ref-type="table"}). There were 128 affected patients identified. This resulted in the identification of 61 different F8 gene mutations. The mutation detection rate was 100%.

###### 

The detailed patient data.

  Case number   Gender   Diagnosis       Result                                                                                Reported/Novel   HRM result            FVIII:C   Severity
  ------------- -------- --------------- ------------------------------------------------------------------------------------- ---------------- --------------------- --------- ----------
  69-1          M        Affected case   Exon 1 deletion                                                                       R                                      \<1%      severe
  61-1          M        Affected case   Exon 2, c.185, C\>G, TCA\>TGA, Ser\>X                                                 N                                      \<1%      severe
  109           M        Affected case   Exon 3, c.278, C\>T, CCT\>CTT, Pro\>Leu                                               N                V                     \<1%      severe
  82            M        Affected case   Exon 3, c.278, C\>T, CCT\>CTT, Pro\>Leu                                               N                                      \<1%      severe
  144           M        Affected case   Exon 3, c.336_339, dup CCAT                                                           N                indistinguishable     1.6%      moderate
  71-1          F        Carrier         Intron 3, c.289-9 C\>T                                                                N                V                               
  42-3          M        Affected case   Exon 4, c.403 G\>A, GAT\>AAT, Asp\>Asn                                                N                                      \<1%      severe
  59-1          M        Affected case   Exon 4, c.532, C\>G, CTT\>GTT, Leu\>Val                                               N                                      \<1%      severe
  118-1         M        Affected case   Exon 4\~Exon 10 deletion                                                              R                                      1.1%      moderate
  122           M        Affected case   Exon 7, c.829, A\>G, ATT\>GTT, Asp\>Gly                                               N                V                     12%       muld
  114           M        Affected case   Exon 7, c.854_855, ins G                                                              N                V                     2.4%      moderate
  79-1          M        Affected case   Exon 7, c.977 T\>C, CTA\>CCA, Leu\>Pro                                                R                                      \<1%      severe
  94-1          M        Affected case   Exon 7, c.977 T\>C, CTA\>CCA, Leu\>Pro                                                R                                      \<1%      severe
  16-3          M        Affected case   Exon 8, c.1247, C\>T, CCC\>CTC, Pro\>Leu                                              N                                      4.2%      moderate
  101           F        Carrier         Exon 9, c.1310 G\>C, CGG\>CCG, Arg\>Pro                                               R                V                               
  72-1          M        Affected case   Exon 9, c.1315 G\>A, GGT\>AGT, Gly\>Ser                                               R                                      3.0%      moderate
  162           M        Affected        Exon 9, c.1336, C\>T, CGA\>TGA, Arg\>X                                                R                                      4.8%      moderate
  110           M        Affected case   Exon 9, c.1400, T\>G, ATC\>AGC, Ile\>Ser                                              N                V                     0.6%      severe
  65            M        Affected case   Exon 11, c.1636, C\>T, CGG\>TGG, Arg\>Trp                                             R                                      2.3%      moderate
  92            M        Affected case   Exon 11, c.1648, C\>T, CGC\>TGC, Arg\>Cys                                             R                                      12.0%     mild
  136           M        Affected case   Exon 11, c.1678, A\>G, AGA\>GAA, Arg\>Gly                                             N                V                     11.0%     moderate
  98            M        Affected case   Exon 12, c.1783_1790 del 8 mer                                                        N                V                     \<1%      severe
  119           M        Affected case   Exon 12, c.1804, C\>T, CGA\>TGA.Arg\>X                                                R                V                     1.5%      moderate
  150-1         M        Affected case   Exon 12, c.1834, C\>T, CGC\>TGC, Arg\>Cys                                             R                                      6.0%      mild
  10-1          M        Affected case   Exon 14, c.2314 C\>T, CAA\>TAA, Gln\>X                                                R                                      \<1%      severe
  104-1         M        Affected case   Exon 14, c.2605_2606, ins C                                                           N                V                     \<1%      severe
  113-1         M        Affected case   Exon 14, c.2609_2610, del CT                                                          R                V                     \<1%      severe
  85-1          M        Affected case   Exon 14, c.2939_2940, ins G                                                           N                V                     \<1%      severe
  124           M        Affected case   Exon 14, c.3294_3295, ins A                                                           N                V                     0.2%      severe
  111           M        Affected case   Exon 14, c.3629, del A                                                                R                V                     \<1%      severe
  17-1          F        Carrier         Exon 14, c.3629, del A                                                                R                                                
  3-1           M        Affected case   Exon 14, c.3629, del A                                                                R                                      \<1%      severe
  132           M        Affected case   Exon 14, c.4076 G\>A, TGG\>TAG, Trp\>X                                                R                                      0.3%      severe
  87-1          M        Affected case   Exon 14, c.4197 del C                                                                 N                                      3.0%      moderate
  63-1          M        Affected case   Exon 14, c.4372, del A                                                                N                                      3.6%      moderate
  2-1           M        Affected case   Exon 14, c.4619, del T                                                                N                                      \<1%      severe
  11-1          F        Affected case   Exon14, c.4814, C\>A, TCA\>TAA, Ser\>X                                                R                                      2.0%      moderate
  57-2          M        Affected case   Exon 14, c.4856, del C                                                                R                                      \<1%      severe
  67-3          M        Affected case   Exon 14, c.4942 C\>T, CAA\>TAA, Gln\>X                                                                                       2.6%      moderate
  115-1         M        Affected case   Exon 14, c.5069_5073, del 5 mer                                                       R                V                     \<1%      severe
  74            M        Affected case   Exon14, c.5143, C\>T, CGA\>TGA, Arg\>X                                                N                                      \<1%      severe
  39-3          M        Affected case   Exon 15, c5343 T\>A, TATA\>TAA, Tyr\>X                                                N                                      \<1%      severe
  48-5          M        Affected case   Exon 15, c.5353, G\>A, GAA\>AAA, Glu\>Lys                                             N                V                     3.7%      moderate
  159-2         M        Affected case   Exon 16, c.5399, G\>A, CGT\>CAT, Arg\>His                                             R                                      4.5%      moderate
  97            M        Affected case   Exon 16, c.5465_5466, insA                                                            N                                      4.9%      moderate
  55-1          M        Affected case   Exon 16, c.5526, G\>A, ATG\>ATA, Met\>Ile                                             R                                      2.1%      moderate
  5-2           M        Affected case   Exon 16, c.5536, T\>A, AAA\>TAA, Lys\>X                                               R                                      1.6%      moderate
  123           M        Affected case   Exon 16, c.5576, A\>G, GAT\>GGT, Asp\>Gly                                             N                indistinguishable     1.3%      moderate
  161-1         F        Carrier         Exon 17, c.5711, A\>G, GAG\>GGG, Glu\>Gly                                             N                V                               
  56-1          M        Affected case   Exon 17, c.5848, C\>T, CGA\>CAA, Gln\>X                                               N                                      \<1%      severe
  1-1           M        Affected case   Exon 18, c.5879, G\>A, CGA\>CAA, Arg\>Gln                                             R                                      7.4%      mild
  133           M        Affected case   Exon 18, c.5879, G\>A, CGA\>CAA, Arg\>Gln                                             R                                      5.5%      mild
  107-1         M        Affected case   Exon 18, c.5953, C\>T, CGA\>TGA, Arg\>X                                               R                V                     0.8%      severe
  138-2         M        Affected case   Exon 18, c.5953, C\>T, CGA\>TGA, Arg\>X                                               R                                      \<1%      severe
  73            M        Affected case   Exon 22, c.6403, C\>T, CGA\>TGA, Arg\>X                                               N                                      \<1%      severe
  14-2          M        Affected case   Exon 23, c.6506, G\>A, CGT\>CAT, Arg\>His                                             R                                      25%       mild
  20-1          M        Affected case   Exon 23, c.6506, G\>A, CGT\>CAT, Arg\>His                                             R                                      2.9%      moderate
  139-1         M        Affected case   Exon 23, c.6506, G\>A, CGT\>CAT, Arg\>His                                             R                V                     3.0%      moderate
  125           M        Affected case   Exon 23, c.6532, C\>T, CGC\>TGC, Arg\>Cys                                             R                                      6.5%      mild
  170-1         M        Affected case   Exon 23, c.6532 C\>T, CGC\>TGC, Arg\>Cys                                              R                V                     8.9%      mild
  174-1         M        Affected case   Exon 23, c.6532 C\>T, CGC\>TGC, Arg\>Cys                                              R                V                     8.4%      mild
  95-1          M        Affected case   Exon 23, c.6545, G\>A, CGC\>CAC, Arg\>His                                             R                V                     2.5%      moderate
  38-3          M        Affected case   Exon 24, c. 6575 G\>T, AGT\>ATT, Ser\>Ile                                             R                                      7.2%      mild
  102-1         M        Affected case   Exon 24, c.6671, C\>T, CCT\>CTT, Pro\>Leu                                             R                V                     2.7%      moderate
  12-1          F        Affected case   Exon 24, c.6683 G\>A, CGA\> CAA, Arg\>Gln                                             R                                      \<1%      severe
  41-3          M        Affected case   Exon 25, c.6724, G\>A, GTG\>ATG, Val\>Met; Exon 8, c.1172, G\>A, CGC\>CAC, Arg\>His   R;R              indistibuishable; V   \<1%      severe
  84-1          M        Affected case   Exon 25, c.6794_6795 del AG                                                           R                indistinguishable     \<1%      severe
  93-1          M        Affected case   Intron 1 inversion                                                                    R                                      12.0%     mild
  21-1          M        Affected case   Intron 22 inversion/Exon14 c.4531, G\>A, GTT\>ATT, Val\>Ile                           R;N              V                     \<1%      severe
  100           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  103-1         F        Carrier         Intron 22 inversion                                                                   R                                                
  105           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  106-1         M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  112-1         M        Affected case   Intron 22 inversion                                                                   R                                      1.2%      moderate
  116-1         M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  117           M        Affected case   Intron 22 inversion                                                                   R                                      3.0%      moderate
  120-1         M        Affected case   Intron 22 inversion                                                                   R                                      2.0%      moderate
  121           M        Affected case   Intron 22 inversion                                                                   R                                      0.6%      severe
  126-1         M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  131-1         M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  13-4          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  140           M        Affected case   Intron 22 inversion                                                                   R                                      1.1%      moderate
  143-1         M        Affected case   Intron 22 inversion                                                                   R                                      3.0%      moderate
  147           M        Affected case   Intron 22 inversion                                                                   R                                      0.5%      severe
  149-2         M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  151           M        Affected case   Intron 22 inversion                                                                   R                                      1.4%      moderate
  15-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  152           M        Affected case   Intron 22 inversion                                                                   R                                      2.1%      moderate
  153           M        Affected case   Intron 22 inversion                                                                   R                                      1.8%      moderate
  154           M        Affected case   Intron 22 inversion                                                                   R                                      0.5%      severe
  155           M        Affected case   Intron 22 inversion                                                                   R                                      1.7%      moderate
  156           M        Affected case   Intron 22 inversion                                                                   R                                      1.8%      moderate
  164           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  167           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  181           M        Affected case   Intron 22 inversion                                                                   R                                      3.0%      moderate
  31-7          F        Carrier         Intron 22 inversion                                                                   R                                                
  33-3          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  34-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  35-1          M        Affected case   Intron 22 inversion                                                                   R                                      3.0%      moderate
  40-2          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  47-1          M        Affected case   Intron 22 inversion                                                                   R                                      3.2%      moderate
  58-3          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  60-1          M        Affected case   Intron 22 inversion                                                                   R                                      1.6%      moderate
  6-1           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  51-1          M        Affected case   Intron 22 inversion                                                                   R                                      2.7%      moderate
  62-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  64-2          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  68-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  70-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  75-2          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  76-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  77-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  81            M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  86-2          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  88-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  89-1          M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  90            M        Affected case   Intron 22 inversion                                                                   R                                      0.8%      severe
  91            M        Affected case   Intron 22 inversion                                                                   R                                      1.1%      moderate
  9-1           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  96-2          M        Affected case   Intron 22 inversion                                                                   R                                      0.5%      severe
  99            M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe
  148           M        Affected case   Intron 22 inversion                                                                   R                                      \<1%      severe

Screening of the F8 intron inversion
------------------------------------

There were fifty-three (42.7%) families with intron 22 inversion (Fig. [1a](#F1){ref-type="fig"}) and one (0.8%) family with intron 1 inversion (Fig. [1b](#F1){ref-type="fig"} &[1c](#F1){ref-type="fig"}) in this study. Since the intron 1 and the intron 22 inversion were well established causative mutations \[[@B3]\], there would be no need to search for other mutations in the coding regions in these families.

![**Result of inversion detection of intron 1 and intron 22**. a) LD-PCR result of intron 22 inversion. Wild type has two band with PQ segment (12 KB) and AB segment (10 KB). With intron 22 rearrangement, PQ segment will be interrupted so that PB and AQ (both 11 KB) form. That is why we can see all three bands in carrier. Patient will show only 11 KB and 10 KB bands. Patient 154 is proved to be an affected case. M, marker. C, carrier. P, known affected male patient. WT, wild type. b) PCR result of intron 1 inversion. Set 1 is the product of primer 9F, int-2F and 9CR. In wild type, the only segment amplified is 1908 bp. In the affected male patient with intron 1 inversion, the amplified segment is 1323 bp in length. c) Set 2 is the product of primer 9F, int-2F and 2R. 93-2, 104-1 and 104-2 are normal. 93-1 is proved to be an affected case. 93-3 is a carrier with heterogenous components.](1471-2350-9-53-1){#F1}

Screening of the *F8*mutation by DHPLC and direct sequencing
------------------------------------------------------------

We performed DHPLC for mutation screening in those families who didn\'t have intron 1 and intron 22 inversions. By DHPLC, 100% genetic mutation was detected in the 119 HA families and confirmed by sequencing. The two X chromosomes from the carriers are responsible for the heteroduplex formation of the PCR amplicons. These stutter peaks (heteroduplex) were eluted much earlier in the chromatographic process than the main peaks (homoduplex). Yet, the affected male patients with one X chromosome would not form a heteroduplex until it is mixed together with the wild type DNA (Fig. [2](#F2){ref-type="fig"}).

![**Result of DHPLC**. DHPLC results of two families were illustrated. a) Family 85. b) Family 139. The wild type DNA showed homoduplex. The carrier DNA would show heteroduplex peak just as affected male after mixing with normal DNA.](1471-2350-9-53-2){#F2}

Evaluating of High-Resolution Melting Analysis
----------------------------------------------

In order to evaluate the HRM analysis, 25 families, including a total of 43 samples with known mutation and 341 normal controls were tested. The mutations consisted of 13 different missense mutations, 5 deletions, 4 insertions, 2 nonsense mutations, one splicing site nucleotide substitution and one duplication.

In order to avoid DNA-dimer formation, we redesigned the primers for the HRM PCR reaction. The resulting melting curves were easier to differentiate from normal controls and the sensitivity was elevated. Figure [3](#F3){ref-type="fig"} compares the melting curves of the original and modified primers, respectively. As temperature increased, the double strand DNA was unwound and the fluorescence was released (Fig [3a](#F3){ref-type="fig"} and [3b](#F3){ref-type="fig"}). The melting curves were normalized by calculation of the \"line of best fit\" in between two normalization regions before and after the major fluorescence decrease representing the melting of the PCR product using the software the LightCycler^®^Gene Scanning Software 4.0. The samples with high signal difference would present different peaks from the wild type (Fig [3d](#F3){ref-type="fig"}).

![**Comparison of the results of different HRM primers**. a) and c) are HRM plots for exon 14-5 with first-designed primer. We are unable to see the grouping in the normalized, temperature-shifted plot. So we redesigned the primer pairs by LightCycler Probe Design Software 2.0. The result is shown in b) and d). The carrier and the patient are easy to be distinguished in the latter.](1471-2350-9-53-3){#F3}

The different melting curve patterns were easily identified in 25 out of 28 cases (89%) and 15 out of 15 (100%) carriers. The sensitivity of HRM in this study was 93 % (40/43).

In addition, we performed HRM for whole coding region scanning in three families with unknown mutations. Three abnormal melting curves were identified. After these exons were confirmed by direct sequencing, we were able to identify the mutation in these three families. The specificity of HRM in this pilot study was high but it required further investigation. A larger sample sizes was needed for validation.

Multiplex PCR
-------------

There were two families, which we were unable to see the exon 4 to exon 10 band and the Exon1 band from electrophoresis after PCR, respectively. For the former, we designed the multiplex PCR that showed a total deletion from exon 4 to exon 10 (Fig [4](#F4){ref-type="fig"}). The ratio of the defective exon to the control gene in peak heights (the exon 4 to exon 10/the KRIT and the exon 4 to exon 10/the FGFR2) in the female carrier was half of that of the wild type. That is, the relative gene dosage in exon 4 to the exon 10 of the wild type was two times to that of the female carrier. As for the other family, we were unable to perform the multiplex PCR without having the DNA of the obligate carrier.

![**Multiplex PCR in a family with exon 4 to exon 10 deletion**. FGFR2 (\*) and KRIT (\#) gene are used as internal control. a) are from wild type and b) are from female carrier. The X axis was time, which also represented the size of the amplicon. The Y axis was the fluorescence intensity of each amplicon, which also represented the relative gene dosage. The relative peak height of the female carrier with arrow is half to that of the wild type in exon 4, 5, 8,9 but not in exon 11.](1471-2350-9-53-4){#F4}

In this study we identified twenty-eight missense mutations, thirteen nonsense mutations, one four- base pair duplication, five insertions, nine small deletions, one splicing site nucleotide substitution and two large segment deletions in the F8 gene.

We identified twenty-nine novel mutations of the F8 gene in hemophilia A patients, in which eleven were missense mutations, one was splicing site substitution, seven were nonsense mutation, which lead to premature terminating of the protein, and ten were frameshift mutations including one four-base pair duplication, four deletions and five insertions, resulting in truncations of the F8 protein. None of the novel missense mutations were presented in the 150 normal DNA samples.

Discussion
==========

The most common mutation, found in approximately 40% of patients with severe hemophilia A, was the intron 22 inversion mutation \[[@B23]\]. This mutation happens when homologous recombination occurs between the Int22h-1 in intron 22 and 1 of 2 homologous regions (Int22h-2 or Int22h-3) telomeric to the F8 gene. An additional inversion of intron 1 of the factor VIII gene that affects up to 5% of patients with severe hemophilia A has been reported \[[@B18]\]. The large size of the F8 gene predisposes to the occurrence of deletions, which account for approximately 5% of characterized mutations. Single base pair changes (resulting in missense, frameshift, or splice junction mutations), insertions, or duplications account for the balance of cases of hemophilia A that are spread throughout the F8 gene \[[@B24]\]. Although the structure-function relationships of some of the missense mutations are known or can be deduced (eg, alteration of vWF binding site, thrombin cleavage site, etc), the structural consequences of most such mutations remain undefined \[[@B25]\].

Our data showed a mutation detection rate at 100% out of 122 hemophilia A families. Since the intron 22 inversion and intron 1 inversion present in 45.1 % in this Taiwanese database, 47.5 to 53% in India population \[[@B8],[@B26]\] and 40--50% in European \[[@B3],[@B18]\], it is rational to perform the inversion detection of intron 1 and intron 22 at first, and then genetic scan if no intron 1 or 22 inversion were found. In our cohort, 54.5% severe HA families had intron 1 and intron 22 inversion; 65.5% cases with intron 1 and intron 22 inversion belonged to severe hemophilia A patients. It is also suggested to check for intron 1, intron 22 inversion and big deletions in cases having the severe phenotype; on the other hand, it is recommended to go directly to the F8 gene mutation scanning in cases having the moderate/mild phenotype \[[@B25],[@B27]\]. However, we are a referred center and the clinical data is not always available. Because the inversion detection of intron 1 and intron 22 is cheaper and more time-saving than other techniques, our strategy seemed to be economical under this situation.

The B domain accounts for 40% of the F8 cDNA. Apart from large exon or intron deletions, fourteen (14/52, 26.9%) different mutations and one SNP were found to be located in the B domain of the F8 cDNA. All mutations belonging to deletion, insertion, or nonsense mutations, lead to different protein products. This may imply the low functional importance of this region since no phenotype would be identified unless the protein product is changed or truncated. The SNP identified in the B domain was located in c. 3780 on exon 14, which changed aspartic acid to glutamic acid. Through family studies in a Caucasian population, Machiah et al. hypothesized that Asp1241Glu influences about 5% F8 levels and modifies thrombosis risk by modulating the rate of secretion into the circulation by family studies \[[@B28]\]. Scanavini et al. also conducted a case-control study and demonstrated that the F8 D1241E polymorphism was associated with decreased F8 activity \[[@B29]\].

Affected males with large deletions can be readily detected by the absence of an amplification product in PCR. Up to 98% of all frequent deletions can be detected, but in carriers, the nondeleted X chromosome hampers detection, making identification of hemophilia A carrier status difficult. In one particular family, the PCR product of an affected male patient failed to show exon 4 to exon 10. But of the same family, the same exon region in the female cases was successfully amplified by PCR and sequenced. Large deletion was suspected, but we were unable to distinguish the female carriers from the wild type. We designed the multiplex PCR \[[@B12],[@B15]\] so that we could differentiate between them by examining different peak heights with the use of different gene dosages(Fig [4](#F4){ref-type="fig"}). In addition, the absence of peaks from exon 4 to exon 10 confirmed the deletion in the affected male. Multiplex PCR is an in-house designed reaction, which compares the dosage of several genes. This system may also be adapted for diagnostic use in other genetic diseases involving deletion and duplication mutations.

We had two heterozygous females from two unrelated families. Hemophilia A is transmitted through heterozygous females denoted as carriers, who are generally asymptomatic. This is because random X inactivation results in approximately equal proportions of somatic cells, in which either the normal X or the mutated X chromosome is active \[[@B23],[@B30]\]. Because females have two X chromosomes and only 5% of FVIII is enough for the body to maintain hemostasis, it is very rare to have a female HA patient with very low FVIII activity and severe bleeding symptoms \[[@B31]\]. Even though the disease is extremely rare in females, a few cases have been documented as a result of different pathophysiologic mechanisms \[[@B32]-[@B34]\]. The skewed X-chromosome inactivation is the most common possible mechanism for the phenomenon \[[@B31],[@B35]-[@B39]\].

The hemophilia A mutation screening is laborious and expensive, even when employing DHPLC as a screening method. In order to facilitate throughput and minimize the cost of hemophilia A mutation screening, we evaluated a new mutation scanning technique, high resolution melting system(HRM). We performed high resolution melting analysis on 43 samples, including carriers and affected cases. All the carriers were easily to be distinguished (100%). Nevertheless, we were unable to identify three out of 28 affected cases. The detection rate was 93%. We had a reason to believe that it is easier for the heteroduplex to release double-stranded DNA dye, so that HRM is more sensitive to carrier detection. DHPLC is not ideal in detecting affected case until mixed together with normal DNA. On the other hand, even though HRM was able to distinguish the affected male from the wild type, the sensitivity did not reach 100% despite optimizing condition. Therefore, mixing up the affected male DNA with normal control would improve the detection rate for both DHPLC and HRM. Besides, we proved that the analysis was greatly enhanced by good primer design that avoided DNA-dimer formation. The sensitivity of the analysis was not only influenced by the size of PCR products but also the primers and the PCR condition. We recommend the software, LightCycler Probe Design Software 2.0, as the tool for primer design.

As for clinical application, once the intron 1 and 22 inversion has been ruled out, HRM becomes a good initial screening method, especially for those families with obligate carriers. Comparing with our familiar method, DHPLC, HRM costs less (\$0.6 versus \$3.0 per sample per amplicon, respectively), takes less time (3 hours versus 10 hours) and works more efficiently (96 or 384 wells at one time). The analysis of HRM takes only fifteen minutes. With this highly sensitive and specific tool, we will be able to manage a large quantity of clinical samples and do mutation screening.

Conclusion
==========

In conclusion, we are capable of detecting 100% of mutations in the F8 gene; also our study identified a number of novel mutations in the largest cohort of Taiwanese patients yet to be reported. Furthermore, we validate HRM for hemophilia A mutation screening. Mutation detection is best started with obligate carriers. We proposed a cost-effective screening protocol with sequential combination of different genetic diagnostic tools. HRM saves time and money, and we have proven the use of such technique to be effective for mutation screening.
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